UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000029476
Receipt number R000033413
Scientific Title Phase II study of combination chemotherapy of Carboplatin, Pemetrexed, Bevacizumab and Erlotinib in patients with advanced non-squamous non-small cell lung cancer harboring EGFR active mutation.
Date of disclosure of the study information 2017/10/30
Last modified on 2023/10/14 10:43:11

No. Disposal Last modified on Item of update
1 Insert 2017/10/09 18:26:56
2 Update 2017/10/29 13:31:10 Date of disclosure of the study information
3 Update 2017/10/30 14:03:10 Date of disclosure of the study information
4 Update 2017/10/30 14:55:48 Institutions
5 Update 2018/12/25 03:21:33 Recruitment status
6 Update 2018/12/25 03:31:36 Key inclusion criteria
Key inclusion criteria
7 Update 2018/12/25 04:30:07 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
8 Update 2018/12/26 11:42:58 Key exclusion criteria
Key exclusion criteria
9 Update 2019/03/22 14:26:59 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Organization
Organization
Address
Address
Tel
Email
10 Update 2019/03/22 14:47:11 Recruitment status
Date of IRB
Last follow-up date
Other related information
11 Update 2019/09/08 22:09:32 Recruitment status
Last follow-up date
Date analysis concluded
12 Update 2021/04/12 09:55:11 Recruitment status
13 Update 2022/04/13 09:22:29 Number of participants that the trial has enrolled
14 Update 2023/10/14 10:43:11 Other related information